乳腺癌组织中c-erbB-2 p53 PCNA及bcl-2蛋白的表达及其临床意义

目的:探讨生物学指标c-erbB-2、p53、PCNA及bcl-2在乳腺癌中的表达与乳腺癌病理生物学行为的关系.方法:应用免疫组织化学方法对56例乳腺癌组织切片c-erbB-2、p53、PCNA及bcl-2的表达进行检测.结果:c-erbB-2表达41.1%,与组织学分级呈正相关,与临床分期、病理类型、患者年龄(≥35岁)、ER、PR受体关系不密切;p53蛋白表达48.2%,与组织学分级、ER、PR受体呈正相关,与患者年龄(≥35岁)、临床分期、病理类型呈负相关;全组PCNA表达100%;bcl-2表达50.0%,与组织学分级、病理类型、ER、PR受体呈负相关,与临床分期呈正相关,与患者年龄(≥35岁)关系不密切.结论:生物学指标c-erbB-2、p53、PCNA及bcl-2应与临床预后因素临床期别、组织学分级等联合应用,提高对乳腺癌预后评价的正确性.

The Expression of c-erbB-2, p53, PCNA and bcl-2 in Breast Cancer and Its Clinical Significance

Objective: To detect the correlation of the expression of c-erbB-2, p53, PCNA and bcl-2 with the biological behavior of breast cancer. Methods: We used immunohistochemistry to detect the expression of c-erbB-2, p53, PCNA and bcl-2 in 56 breast cancer patients. Results: The expression of c-erbB-2 was 41.1% and was negatively correlated with histological classification but was not correlated with age, clinical stage, ER, or PR. The expression of p53 was 48.2% and was positively related with ER and PR but was negatively correlated with clinical stage and pathological type. The expression of bcl-2 was 50.0% and was negatively correlated with histological classification, ER and PR and was positively correlated with clinical stage and pathological type. PCNA was highly expressed in the 56 cases. Conclusion: We should combine the detection of c-erbB-2, p53, PCNA and bcl-2 with the evaluation of clinical stage, histological degree and pathological type in order to improve the prognostic estimation of breast cancer.